Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Evommune Inc. (EVMN), a clinical-stage biotechnology company, filed a registration statement with the Securities and Exchange Commission on October 17 for an initial public offering of its common stock.
The Palo Alto-based company is offering 9,375,000 shares at an expected price between $15.00 and $17.00 per share. Evommune also plans to grant underwriters a 30-day option to purchase up to an additional 1,406,250 shares.
The company has applied to list its common stock on the New York Stock Exchange under the ticker symbol "EVMN."
According to the press release, the registration statement is expected to become automatically effective on November 5, 2025, under Section 8(a) of the Securities Act. Evommune expects to complete pricing of the offering on or after that date.
Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are serving as joint book-running managers for the proposed offering.
Evommune develops therapies targeting chronic inflammatory diseases. The company stated its mission is to improve patients’ daily lives and prevent long-term effects of uncontrolled inflammation.
The registration statement has been filed but has not yet become effective. The securities cannot be sold until the registration statement becomes effective.